Xenon New Long-Term Azetukalner Data Shows Sustained Monthly Reductions In Seizure Frequency Maintained At 85% At OLE Study Month 36; Approximately 1/3 Patients On Drug For At Least 36-Months Achieved Seizure Freedom For A Period Of 1-Year Or Longer
Xenon New Long-Term Azetukalner Data Shows Sustained Monthly Reductions In Seizure Frequency Maintained At 85% At OLE Study Month 36; Approximately 1/3 Patients On Drug For At Least 36-Months Achieved Seizure Freedom For A Period Of 1-Year Or Longer
– OLE data shows sustained monthly reduction in seizure frequency, impressive seizure freedom rates, and consistent AE safety profile suggesting long-term efficacy and tolerability of azetukalner
– OLE數據表明，每月持續減少癲癇發作頻率，令人印象深刻的無癲癇發作率，以及穩定的AE安全性特徵，表明azetukalner的長期療效和耐受性
– Approximately one in three patients on drug for at least 36 months achieved seizure freedom for a period of one year or longer
– 大約三分之一的患者在用藥至少36個月後，有一年或更長時間的無癲癇發作經歷
– Sustained monthly reductions in seizure frequency maintained at 85% at OLE study month 36
– 在OLE研究的第36個月，每月癲癇發作頻率的持續減少保持在85%
– Patient-reported survey data and literature review illustrate significant mental health and comorbidity burdens of focal onset seizures highlighting areas of unmet need for people living with epilepsy
– 患者報告的調查數據和文獻回顧顯示，局部發作癲癇的顯著心理健康和合並症負擔，突顯了癲癇患者未滿足需求的領域
– New pre-clinical data shows Nav1.1 potentiator provides protection against spontaneous seizures and SUDEP in pre-clinical Dravet model
– 新的臨床前數據表明，Nav1.1增強劑能在臨床前Dravet模型中提供對自發性癲癇發作和SUDEP的保護
譯文內容由第三人軟體翻譯。